Bio-Path Holdings Set to Reveal Third Quarter Financials

Upcoming Announcement from Bio-Path Holdings

HOUSTON — Bio-Path Holdings, Inc. (NASDAQ: BPTH), a pioneering biotechnology firm, is gearing up to unveil its financial results for the third quarter. The announcement will take place in a live conference call and audio webcast scheduled for Friday at 8:30 a.m. ET. Investors and stakeholders can look forward to insights into the company’s financial performance and a comprehensive business overview.

How to Join the Conference Call

Individuals interested in participating in the live conference call should dial (844) 481-3014 for domestic calls or (412) 317-1879 for international access. It is advisable to connect at least five minutes ahead of the scheduled start time to avoid any technical delays. Additionally, those who prefer to listen online can access the live audio webcast directly from the Presentations section of Bio-Path's website.

Audio Webcast Availability

An archived version of the webcast will be made available on the company’s website approximately two hours following the conclusion of the event, allowing those who cannot attend live to catch up on the important information shared during the call.

About Bio-Path Holdings, Inc.

Bio-Path is recognized for its innovative DNAbilize® technology, which has led to the development of a promising portfolio of RNAi nanoparticle drugs. These drugs can be delivered through simple intravenous transfusions, making treatment simpler for patients. The company's lead candidate, prexigebersen (BP1001), is currently in a Phase 2 study focusing on blood cancers. This drug specifically targets the Grb2 protein, a critical factor in cancer cell survival and proliferation.

Leading Drug Candidates

Another significant candidate in Bio-Path's development pipeline is BP1001-A, a modified version of prexigebersen, which is being evaluated in a Phase 1/1b study for solid tumors. Furthermore, BP1002, which targets the Bcl-2 protein, is under investigation for its effectiveness against blood cancers and solid tumors such as lymphoma and acute myeloid leukemia. The company is also preparing to file an Investigational New Drug (IND) application for BP1003, a sophisticated antisense oligodeoxynucleotide designed to inhibit the STAT3 protein.

Partnerships and Future Directions

Bio-Path Holdings is making notable strides in the biomedical field, signaling potential partnerships to help accelerate the development and marketing of its drug pipeline. As the demand for efficient cancer therapies continues to grow, Bio-Path's advanced technologies position the company as a key player in oncology treatment advancements.

Contact Information for Further Queries

For inquiries or additional details about the company’s offerings, interested parties can reach out to the Investor Relations team. Will O’Connor from Stern Investor Relations is available at 212-362-1200, or contact Doug Morris directly at Bio-Path Holdings, Inc. at 832-742-1369.

Frequently Asked Questions

What is Bio-Path Holdings known for?

Bio-Path Holdings is a biotechnology company specializing in developing antisense RNAi nanoparticle technologies for cancer treatment.

When is the financial results announcement?

The announcement of the financial results for the third quarter of 2024 is scheduled for November 15, 2024.

How can I access the conference call?

You can join the conference call by calling (844) 481-3014 domestically or (412) 317-1879 internationally.

What are Bio-Path's lead drug candidates?

Bio-Path's lead drug candidates include prexigebersen (BP1001) and BP1002, targeting critical proteins associated with various cancers.

Where can I find more information about Bio-Path?

More information can be found on Bio-Path's official website, providing updates on their projects and initiatives.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.